Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025
June 27 2022 - 8:00AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company,
today announced that the Company has extended its Cooperative
Research and Development Agreement (CRADA) with the National Cancer
Institute (NCI), an institute of the National Institutes of Health,
using the Alaunos Sleeping Beauty technology through January 2025.
Under the terms of the CRADA, the NCI will work
to generate proof of concept utilizing the Company’s proprietary
non-viral Sleeping Beauty technology for personalized TCR-T cell
therapy. In this setting, T-cell receptors (TCRs) that react to the
patient’s tumor will be identified from the patient and used to
generate a TCR-T cell therapy. This approach could potentially
apply to a wide range of solid tumor cancer patients. Alaunos
believes that the non-viral Sleeping Beauty technology could
rapidly and cost effectively produce safe and potent TCR-T cell
therapies without the complexity of gene editing or viral
approaches. Research conducted under the CRADA will be led by
Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at
the NCI's Center for Cancer Research.
“We are privileged to extend the productive
collaboration with Dr. Rosenberg, a cell therapy pioneer. Dr.
Rosenberg and the NCI are working to develop personalized cancer
therapies using our novel TCR-T cell platform,” commented Kevin S.
Boyle, Sr., Chief Executive Officer of Alaunos. “Our collaboration
reinforces our commitment to improving the lives of cancer patients
with solid tumors. We look forward to continuing our collaborating
with Dr. Rosenberg and his team to generate proof of concept in
this personalized TCR-T approach.”
Drew Deniger, Ph.D., Vice President, Research
& Development at Alaunos added, “Having worked alongside Dr.
Rosenberg for many years, I am confident that his team at the NCI
will be successful in developing personalized TCR-T therapies using
our non-viral Sleeping Beauty technology. As the world’s experts in
Sleeping Beauty, we believe that our non-viral means of adding the
TCR to T cells is well suited for a personalized approach, with
potential to further increase the addressable population for TCR-T
therapies.”
About
Alaunos TherapeuticsAlaunos is a clinical-stage
oncology-focused cell therapy company, focused on developing T-cell
receptor (TCR) therapies based on its proprietary, non-viral
Sleeping Beauty gene transfer technology and its TCR library
targeting shared tumor-specific hotspot mutations in key oncogenic
genes including KRAS, TP53 and EGFR. The Company has clinical and
strategic collaborations with The University of Texas MD Anderson
Cancer Center and the National Cancer Institute. For more
information, please visit www.alaunos.com.
Forward-Looking Statements
Disclaimer This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as “may,” “will,” “could,” “expects,” “plans,”
“anticipates,” “believes” or other words or terms of similar
meaning. These statements include, but are not limited to,
statements regarding the Company's business and strategic plans,
the anticipated outcome of preclinical and clinical studies by the
Company or its third-party collaborators, the Company's cash
runway, and the timing of the Company's research and development
programs, including the anticipated dates for filing INDs,
enrolling and dosing patients in and the expected timing for
announcing preclinical data and results from the Company’s clinical
trials. Although the management team of Alaunos believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Alaunos, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include, among other
things, changes in the Company’s operating plans that may impact
its cash expenditures; the uncertainties inherent in research and
development, future clinical data and analysis, including whether
any of Alaunos’ product candidates will advance further in the
preclinical research or clinical trial process, including receiving
clearance from the U.S. Food and Drug Administration or equivalent
foreign regulatory agencies to conduct clinical trials and whether
and when, if at all, they will receive final approval from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies and for which indication; the strength and enforceability
of Alaunos’ intellectual property rights; and competition from
other pharmaceutical and biotechnology companies as well as risk
factors discussed or identified in the public filings with the
Securities and Exchange Commission made by Alaunos, including those
risks and uncertainties listed in the most recent periodic report
filed by Alaunos with the Securities and Exchange Commission.
Alaunos is providing this information as of the date of this press
release, and Alaunos does not undertake any obligation to update or
revise the information contained in this press release whether as a
result of new information, future events, or any other reason.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2024 to May 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From May 2023 to May 2024